

Morten Mau-Sørensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8251224/publications.pdf>

Version: 2024-02-01

38
papers

1,849
citations

331670

21
h-index

315739

38
g-index

38
all docs

38
docs citations

38
times ranked

4120
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	670
2	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. <i>Blood</i> , 2018, 131, 855-863.	1.4	105
3	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	9.4	83
4	Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1552-1563.	7.0	65
5	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 728-735.	6.4	64
6	High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer. <i>Npj Genomic Medicine</i> , 2019, 4, 13.	3.8	63
7	Copenhagen Prospective Personalized Oncology (CoPPO)â€”Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1239-1247.	7.0	59
8	Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 899-905.	1.5	55
9	A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1065-1073.	2.3	50
10	Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 723-729.	2.3	46
11	The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 3627-3633.	1.6	44
12	Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. <i>Clinical Therapeutics</i> , 2016, 38, 2286-2299.	2.5	42
13	A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 2730-2736.	7.0	41
14	Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1007-1015.	1.2	38
15	HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 693394.	2.8	38
16	Serum tumor markers in bile duct cancer â€” a review. <i>Biomarkers</i> , 2014, 19, 437-443.	1.9	36
17	A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 258-266.	7.0	32
18	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017, 23, 5406-5415.	7.0	29

#	ARTICLE	IF	CITATIONS
19	A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 452-460.	7.0	29
20	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 858-867.	7.0	28
21	Clopidogrel–Paclitaxel Drug–Drug Interaction: A Pharmacoepidemiologic Study. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 547-553.	4.7	27
22	Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 5655-5667.	7.0	21
23	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. <i>European Journal of Cancer</i> , 2015, 51, 1381-1388.	2.8	19
24	Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 – a retrospective case series. <i>International Journal of Neuroscience</i> , 2016, 126, 1002-1006.	1.6	19
25	Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1165-1174.	3.5	19
26	A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 791-798.	2.3	17
27	TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 485-494.	1.5	15
28	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. <i>Oncotarget</i> , 2018, 9, 32570-32579.	1.8	15
29	Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330). <i>Blood</i> , 2015, 126, 258-258.	1.4	13
30	Application of cell-free DNA for genomic tumor profiling: a feasibility study. <i>Oncotarget</i> , 2019, 10, 1388-1398.	1.8	13
31	Three-year follow-up of implementation of evidence-based transfusion practice in a tertiary hospital. <i>Vox Sanguinis</i> , 2017, 112, 229-239.	1.5	10
32	Detection of copy number alterations in cell-free tumor DNA from plasma. <i>BBA Clinical</i> , 2017, 7, 120-126.	4.1	9
33	Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103339.	4.4	9
34	First-in-human phase 1 dose-escalation study of CANO4, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. <i>British Journal of Cancer</i> , 2022, 126, 1010-1017.	6.4	8
35	Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients. <i>Clinical Biochemistry</i> , 2014, 47, 599-604.	1.9	7
36	Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK+ advanced tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 475-486.	2.3	6

#	ARTICLE	IF	CITATIONS
37	Perioperative exercise training for patients with gastrointestinal cancer undergoing surgery: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 3028-3039.	1.0	4
38	Patients in phase 1 cancer trials: psychological distress and understanding of trial information. <i>Acta Oncologica</i> , 2022, 61, 341-348.	1.8	1